Incidence and risk factors associated with development of clinical cardiotoxicity in dogs receiving doxorubicin
Journal of Veterinary Internal Medicine2019Vol. 33(2), pp. 783–791
Citations Over TimeTop 10% of 2019 papers
Abstract
Although the duration of DOX infusion did not influence the incidence of cardiotoxicity, premature contractions and decreases in fractional shortening should raise concern for the development of clinical cardiotoxicity. Overall, the incidence of clinical DOX-induced cardiotoxicity is low, but Boxers and other breeds at high risk for dilated cardiomyopathy may be at an increased risk.
Related Papers
- → The beneficial role of exercise in preventing doxorubicin-induced cardiotoxicity(2023)21 cited
- → Repeated Remote Ischemic Conditioning Reduces Doxorubicin-Induced Cardiotoxicity(2020)20 cited
- → The Essential Strategies to Mitigate Cardiotoxicity Caused by Doxorubicin(2023)17 cited
- → Cardioprotective Effects of Lignanoid against Doxorubicin-Induced Oxidative Stress in Rat(2013)
- → Research progress on the protective effects of polyphenols against doxorubicin-induced cardiotoxicity(2018)